This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
OPKO Health (OPK) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
Although the revenue and EPS for OPKO Health (OPK) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
OPKO Health (OPK) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
OPKO Health (OPK) delivered earnings and revenue surprises of -33.33% and 5%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
OPKO Health (OPK) to Restructure After Asset Buyout by Labcorp
by Zacks Equity Research
OPKO Health (OPK) expects to re-establish profitability in its clinical laboratory business via its latest efforts to streamline its laboratory services business.
Labcorp (LH) to Boost Clinical Diagnostics With New Deal
by Zacks Equity Research
The recent deal will augment Labcorp's (LH) laboratory services network and expand access to the company's high-quality clinical laboratory services.
OPKO Health (OPK) And Entera Bio Announce Data for GLP-2
by Zacks Equity Research
OPKO Health (OPK) and Entera Bio announce robust pharmacokinetic results for the proprietary GLP-2 agonist developed by OPK Heath.
OPKO Health's (OPK) Q4 Earnings Match Estimates, Revenues Top
by Zacks Equity Research
Despite OPKO Health's (OPK) robust RAYALDEE sales and strength in the Pharmaceuticals segment, its overall fourth-quarter results reflect soft performances.
OPKO Health (OPK) Reports Q4 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
While the top- and bottom-line numbers for OPKO Health (OPK) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
OPKO Health (OPK) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
OPKO Health (OPK) delivered earnings and revenue surprises of 0% and 2%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Gear Up for OPKO Health (OPK) Q4 Earnings: Wall Street Estimates for Key Metrics
by Zacks Equity Research
Beyond analysts' top -and-bottom-line estimates for OPKO Health (OPK), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2023.
IQVIA Holdings (IQV) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
IQVIA (IQV) delivered earnings and revenue surprises of 0.71% and 2.17%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Shockwave Medical (SWAV) Surges 7.8%: Is This an Indication of Further Gains?
by Zacks Equity Research
Shockwave Medical (SWAV) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Here's Why You Should Retain OPKO Health (OPK) Stock for Now
by Zacks Equity Research
OPKO Health's (OPK) potential in Rayaldee raises optimism about the stock.
Why Is OPKO Health (OPK) Up 18.7% Since Last Earnings Report?
by Zacks Equity Research
OPKO Health (OPK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
OPKO Health (OPK) Q3 Earnings Lag Estimates, Revenues Top
by Zacks Equity Research
Despite OPKO Health's (OPK) robust RAYALDEE sales and strength in the Pharmaceuticals segment, its overall third-quarter results reflect soft performances.
OPKO Health (OPK) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
Although the revenue and EPS for OPKO Health (OPK) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
OPKO Health (OPK) Gets BARDA Contract to Combat Antibody Threats
by Zacks Equity Research
OPKO Health's (OPK) latest awarded funding is likely to enable the development of novel multispecific antibodies against viral infectious disease threats.
OPKO Health (OPK) Ties Up for Oral Peptide Tablet Formulations
by Zacks Equity Research
OPKO Health's (OPK) latest Research Collaboration Agreement is likely to enable it to expand its pipeline to develop orally administered tablet presentations of long-acting peptides.
Reasons to Retain OPKO Health (OPK) Stock in Your Portfolio
by Zacks Equity Research
OPKO Health's (OPK) potential in RAYALDEE raises optimism about the stock.
OPKO Health (OPK) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Despite OPKO Health's (OPK) robust RAYALDEE sales and strength in the Pharmaceuticals segment, its overall second-quarter results reflect soft performances.
OPKO Health (OPK) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
OPKO Health (OPK) delivered earnings and revenue surprises of 57.14% and 39.44%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Intuitive Surgical (ISRG) Q2 Earnings Beat, Procedures Robust
by Zacks Equity Research
Intuitive Surgical's (ISRG) second-quarter results reflect healthy demand for procedures, partially offset by unfavorable currency. COVID-19 impacts procedure volume in China.
Best Momentum Stocks to Buy for July 19th
by Zacks Equity Research
NEOG, OPK and PCOR made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 19, 2023.
New Strong Buy Stocks for July 19th
by Zacks Equity Research
SOHO, FUTU, NEOG, OPK and THRX have been added to the Zacks Rank #1 (Strong Buy) List on July 19, 2023.
Best Momentum Stocks to Buy for July 12th
by Zacks Equity Research
RMTI, ZUO and OPK made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 12, 2023.
Strength Seen in Tandem Diabetes Care, Inc. (TNDM): Can Its 8.9% Jump Turn into More Strength?
by Zacks Equity Research
Tandem Diabetes Care, Inc. (TNDM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.